Bicycle Therapeutics PLC (BCYC): Total Liabilities
$107.62M
As of 2025-12-31
$96.32M
As of 2026-06-30
-8.4%
3-year compound annual growth
+10.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $107.62M | -34.3% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $163.81M | -27.0% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $224.41M | +60.5% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $139.83M | +4.7% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $133.54M | +103.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $65.69M | +286.5% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $17.00M | -41.9% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $29.25M | n/a | 2020-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
Compare BCYC, ASMB, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗